Sequana Medical's Participation at VFB Happening 2025
Sequana Medical NV is excited to announce its participation in the VFB Happening 2025, an influential event showcasing innovation in the healthcare sector. Taking place in the renowned Congress Center ICC in Ghent, the event offers a fantastic opportunity for investors and industry leaders to connect and discuss upcoming trends and technologies.
Insights from Industry Leaders
At this year's VFB Happening, Sequana Medical will feature its leadership team at booth 3060, where discussions and insights will focus on the company’s breakthrough solutions to combat drug-resistant fluid overload. Attendees will have the chance to meet CEO Ian Crosbie and CFO, who will present critical updates regarding the upcoming U.S. launch of the alfapump, slated for mid-Q3.
Understanding Fluid Overload and Its Impacts
Fluid overload is a serious issue faced by patients with liver disease, heart failure, and cancer, presenting significant challenges such as increased mortality and frequent hospitalizations. Traditional diuretics often become ineffective or intolerable over time, leaving limited treatment options that impact patients’ quality of life.
Innovative Approaches by Sequana Medical
Sequana Medical is committed to developing innovative treatments for the millions of individuals affected by diuretic-resistant fluid overload. Its proprietary technologies, the alfapump and DSR, are designed to tackle fluid retention effectively while minimizing healthcare costs. These platforms aim to enhance patient outcomes dramatically.
Recent Developments and Future Plans
The company achieved a significant milestone with the FDA's approval of the alfapump System for treating recurrent ascites linked to liver cirrhosis. Following the FDA's Breakthrough Device Designation granted earlier, Sequana Medical is poised to start U.S. commercialization in mid-Q3 2025, targeting the country’s major liver transplant centers.
Clinical Success and Evidenced Benefits
Recent studies, including the RED DESERT and SAHARA trials published in a leading medical journal, have demonstrated how the DSR platform effectively interrupts the cycle of cardiorenal syndrome. Initial results from a Phase 1/2a clinical study involving three patients receiving DSR treatment revealed a remarkable improvement in patient outcomes, reducing dependency on loop diuretics significantly.
Getting Involved: Registration and Contact Information
Attendance at the VFB Happening is complimentary, but interested individuals must register in advance. This annual conference is a prime opportunity for investors and stakeholders to discover cutting-edge advancements in medical technology and engage with experts like the Sequana Medical team.
For those seeking to learn more or arrange a meeting, please reach out directly:
Contact Sequana Medical:
Investor Relations
Email: IR@sequanamedical.com
Phone: +32 9 292 8065
Frequently Asked Questions
1. What is the VFB Happening 2025?
The VFB Happening 2025 is Belgium’s leading investor conference, offering insights into advancements in healthcare.
2. Who will represent Sequana Medical at the event?
The CEO and CFO of Sequana Medical will be present, along with their Investor Relations team.
3. What is the alfapump?
The alfapump is an innovative system developed by Sequana Medical for treating fluid overload in patients.
4. When is Sequana Medical planning to launch the alfapump in the U.S.?
The launch is scheduled for mid-Q3 2025.
5. How can I contact Sequana Medical for more information?
You can reach out via their investor relations email at IR@sequanamedical.com.
